CALTX.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 11:29):

Stats
Today's Volume	1.35M
Average Volume	434 315
Market Cap	11.17B
EPS	SEK0 ( 2024-05-22 )
Next earnings date	( SEK-0.160 ) 2024-08-13
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-21.27
ATR14	SEK0.0550 (0.03%)

Volume Correlation

Long: 0.23 (neutral)

Short: 1.00 (very strong)

Signal:(56.371) Expect same movement, but be aware

Calliditas Therapeutics Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Calliditas Therapeutics Correlation - Currency/Commodity

-0.21
( neutral )

-0.20
( neutral )

0.00
( neutral )

0.03
( neutral )

-0.21
( neutral )

Calliditas Therapeutics Financials

Annual	2023
Revenue:	SEK1.21B
Gross Profit:	SEK1.13B (93.62 %)
EPS:	SEK-8.69

FY	2023
Revenue:	SEK1.21B
Gross Profit:	SEK1.13B (93.62 %)
EPS:	SEK-8.69

FY	2023
Revenue:	SEK0
Gross Profit:	SEK0 (0.00 %)
EPS:	SEK0

FY	2022
Revenue:	SEK802.88M
Gross Profit:	SEK787.68M (98.11 %)
EPS:	SEK-7.78

Financial Reports:

No articles found.

Calliditas Therapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Calliditas Therapeutics

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.